BRPI0519760A2 - derivados de pirrolidila de compostos heteroaromÁticos como inibidores de fosfodiesterasse - Google Patents
derivados de pirrolidila de compostos heteroaromÁticos como inibidores de fosfodiesterasseInfo
- Publication number
- BRPI0519760A2 BRPI0519760A2 BRPI0519760-0A BRPI0519760A BRPI0519760A2 BR PI0519760 A2 BRPI0519760 A2 BR PI0519760A2 BR PI0519760 A BRPI0519760 A BR PI0519760A BR PI0519760 A2 BRPI0519760 A2 BR PI0519760A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- relates
- inhibitors
- derivatives
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
DERIVADOS DE PIRROLIDILA DE COMPOSTOS HETEROAROMÁTICOS COMO INIBIDORES DE FOSFODIESTERASE. A invenção refere-se a novos derivados de pirrolidila de compostos aza heteroaromáticos benzo fundidos que servem como inibidores de fosfodiesterase (PDE) eficazes. A invenção também se refere a compostos que são inibidores seletivos de PDE-1O. A invenção também se refere a intermediários para preparação de tais compostos; composições farmacêuticas que compreendem tais compostos; e o uso de tais compostos em métodos para tratar certos trasntornos do sistema nervoso central (CNS) ou outros. A invenção também se refere a métodos para tratar transtomos neurodegenerativos e psiquiátricos, por exemplo psicose e distúrbios que compreendem cognição deficiente como um sintoma. Fórmula I.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64040504P | 2004-12-31 | 2004-12-31 | |
PCT/IB2005/003989 WO2006070284A1 (en) | 2004-12-31 | 2005-12-19 | Pyrrolidyl derivatives of heteroaromatic compounds as phosphodiesterase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0519760A2 true BRPI0519760A2 (pt) | 2009-03-10 |
Family
ID=36046318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0519760-0A BRPI0519760A2 (pt) | 2004-12-31 | 2005-12-19 | derivados de pirrolidila de compostos heteroaromÁticos como inibidores de fosfodiesterasse |
Country Status (23)
Country | Link |
---|---|
US (1) | US20060183763A1 (pt) |
EP (1) | EP1838702A1 (pt) |
JP (1) | JP2008526726A (pt) |
KR (1) | KR20070086841A (pt) |
CN (1) | CN101087778A (pt) |
AP (1) | AP2007004004A0 (pt) |
AR (1) | AR055298A1 (pt) |
AU (1) | AU2005321015A1 (pt) |
BR (1) | BRPI0519760A2 (pt) |
CA (1) | CA2594251A1 (pt) |
CR (1) | CR9135A (pt) |
EA (1) | EA200701118A1 (pt) |
GT (1) | GT200500367A (pt) |
IL (1) | IL183188A0 (pt) |
MA (1) | MA29119B1 (pt) |
MX (1) | MX2007006301A (pt) |
NL (1) | NL1030819C2 (pt) |
NO (1) | NO20073958L (pt) |
PE (1) | PE20060775A1 (pt) |
TN (1) | TNSN07248A1 (pt) |
TW (1) | TW200637851A (pt) |
UY (1) | UY29317A1 (pt) |
WO (1) | WO2006070284A1 (pt) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007010572A (es) * | 2005-03-01 | 2007-10-04 | Wyeth Corp | Compuestos de cinolina y su uso como moduladores de receptor x de higado. |
GB0522715D0 (en) | 2005-11-08 | 2005-12-14 | Helperby Therapeutics Ltd | New use |
EP1981868A2 (en) * | 2006-01-27 | 2008-10-22 | Pfizer Products Inc. | Aminophthalazine derivative compounds |
JP2009527562A (ja) * | 2006-02-21 | 2009-07-30 | アムゲン インコーポレイティッド | ホスホジエステラーゼ10阻害剤としてのシンノリン誘導体 |
US20070265256A1 (en) * | 2006-02-21 | 2007-11-15 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
EP1991531A1 (en) * | 2006-02-28 | 2008-11-19 | Amgen Inc. | Cinnoline and quinoxaline derivates as phosphodiesterase 10 inhibitors |
US20090099175A1 (en) * | 2006-03-01 | 2009-04-16 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
AU2007223801A1 (en) * | 2006-03-08 | 2007-09-13 | Amgen Inc. | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
WO2008020302A2 (en) * | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
DK2182950T3 (da) | 2007-05-17 | 2017-11-06 | Helperby Therapeutics Ltd | Anvendelse af 4-(pyrrolidin-1-yl)quinolinforbindelser til at dræbe klinisk latente mikroorganismer |
US8133897B2 (en) | 2008-06-20 | 2012-03-13 | H. Lundbeck A/S | Phenylimidazole derivatives as PDE10A enzyme inhibitors |
UA102693C2 (ru) * | 2008-06-20 | 2013-08-12 | Х. Луннбек А/С | Производные фенилимидазола как ингибиторы фермента pde10a |
TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之新穎苯基咪唑衍生物 |
TWI396689B (zh) * | 2008-11-14 | 2013-05-21 | Amgen Inc | 作為磷酸二酯酶10抑制劑之吡衍生物 |
CA2744987C (en) | 2008-12-02 | 2018-01-16 | Chiralgen, Ltd. | Method for the synthesis of phosphorus atom modified nucleic acids |
BR112012000828A8 (pt) | 2009-07-06 | 2017-10-10 | Ontorii Inc | Novas pró-drogas de ácido nucleico e métodos de uso das mesmas |
WO2012039448A1 (ja) | 2010-09-24 | 2012-03-29 | 株式会社キラルジェン | 不斉補助基 |
DE102010042833B4 (de) | 2010-10-22 | 2018-11-08 | Helmholtz-Zentrum Dresden - Rossendorf E.V. | Neue Halogenalkoxychinazoline, deren Herstellung und Verwendung |
US20120115849A1 (en) * | 2010-11-08 | 2012-05-10 | Demopulos Gregory A | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors |
BR112013021180A2 (pt) | 2011-02-18 | 2019-09-24 | Allergan Inc | derivados de 6,7-dialcóxi-3-isoquinolinol substituído como inibidores de fosfodiesterase 10 (pde10a) |
US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
CA2871151C (en) * | 2012-05-07 | 2019-03-26 | Omeros Corporation | Treatment of addiction and impulse-control disorders using pde7 inhibitors |
KR101835401B1 (ko) | 2012-07-13 | 2018-03-08 | 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. | 키랄 핵산 어쥬번트 |
KR20220139425A (ko) | 2012-07-13 | 2022-10-14 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
AU2013288048A1 (en) | 2012-07-13 | 2015-01-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
ITVI20130032A1 (it) * | 2013-02-14 | 2014-08-15 | F I S Fabbrica Italiana Sint I S P A | Procedimento per la preparazione di n-boc-pirrolidinone |
US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
EP3095461A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
PT3094728T (pt) | 2014-01-16 | 2022-05-19 | Wave Life Sciences Ltd | Desenho quiral |
TW201611834A (en) * | 2014-02-07 | 2016-04-01 | Lundbeck & Co As H | Hexahydrofuropyrroles as PDE1 inhibitors |
ES2776359T3 (es) * | 2014-04-04 | 2020-07-30 | H Lundbeck As | Quinazolin-thf-aminas halogenadas como inhibidores de PDE1 |
WO2016116900A1 (en) * | 2015-01-23 | 2016-07-28 | Gvk Biosciences Private Limited | Inhibitors of trka kinase |
SG11201900349VA (en) | 2016-07-14 | 2019-02-27 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
CN106632089B (zh) * | 2016-11-04 | 2019-06-18 | 中山大学 | 一类喹唑啉类化合物及其制备方法与应用 |
AU2018393409A1 (en) * | 2017-12-26 | 2020-08-13 | Mediconns (Shanghai) Biopharmaceutical Co., Ltd | Tetrahydropyrrole compound, preparation method therefor, pharmaceutical composition containing same, and use thereof |
US11266641B1 (en) | 2020-09-09 | 2022-03-08 | Crinetics Pharmaceuticals, Inc. | Formulations of a somatostatin modulator |
CN115417802A (zh) * | 2021-05-16 | 2022-12-02 | 上海鼎雅药物化学科技有限公司 | 乌帕替尼及其中间体的制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3577432A (en) * | 1968-12-23 | 1971-05-04 | Robins Co Inc A H | 1-substituted-3-phenoxypyrrolidines |
US4306065A (en) * | 1979-12-19 | 1981-12-15 | A. H. Robins Company, Incorporated | 2-Aryl-4-substituted quinazolines |
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
JP3919272B2 (ja) * | 1996-12-18 | 2007-05-23 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キナゾリン系化合物 |
ES2226427T3 (es) * | 1998-08-25 | 2005-03-16 | Ortho-Mcneil Pharmaceutical, Inc. | Esteres y tioeteres de piridillo como agonistas de receptor de acetilcolina nicotinico y aplicacion terapeutica. |
US20020151712A1 (en) * | 1999-09-14 | 2002-10-17 | Nan-Horng Lin | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
KR100621287B1 (ko) * | 2001-05-21 | 2006-09-13 | 에프. 호프만-라 로슈 아게 | 신경 펩타이드 y 수용체에 대한 리간드로서의 퀴놀린유도체 |
US20070021404A1 (en) * | 2003-06-24 | 2007-01-25 | Dan Peters | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
CA2568929A1 (en) * | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
-
2005
- 2005-10-24 US US11/257,179 patent/US20060183763A1/en not_active Abandoned
- 2005-12-14 PE PE2005001461A patent/PE20060775A1/es not_active Application Discontinuation
- 2005-12-15 GT GT200500367A patent/GT200500367A/es unknown
- 2005-12-19 CA CA002594251A patent/CA2594251A1/en not_active Abandoned
- 2005-12-19 MX MX2007006301A patent/MX2007006301A/es unknown
- 2005-12-19 JP JP2007548917A patent/JP2008526726A/ja not_active Withdrawn
- 2005-12-19 BR BRPI0519760-0A patent/BRPI0519760A2/pt not_active Application Discontinuation
- 2005-12-19 AU AU2005321015A patent/AU2005321015A1/en not_active Abandoned
- 2005-12-19 EA EA200701118A patent/EA200701118A1/ru unknown
- 2005-12-19 WO PCT/IB2005/003989 patent/WO2006070284A1/en active Application Filing
- 2005-12-19 KR KR1020077015027A patent/KR20070086841A/ko not_active Application Discontinuation
- 2005-12-19 EP EP05826591A patent/EP1838702A1/en not_active Withdrawn
- 2005-12-19 AP AP2007004004A patent/AP2007004004A0/xx unknown
- 2005-12-19 CN CNA2005800447584A patent/CN101087778A/zh active Pending
- 2005-12-26 AR ARP050105532A patent/AR055298A1/es unknown
- 2005-12-27 UY UY29317A patent/UY29317A1/es not_active Application Discontinuation
- 2005-12-30 NL NL1030819A patent/NL1030819C2/nl not_active IP Right Cessation
- 2005-12-30 TW TW094147577A patent/TW200637851A/zh unknown
-
2007
- 2007-05-14 IL IL183188A patent/IL183188A0/en unknown
- 2007-05-18 CR CR9135A patent/CR9135A/es not_active Application Discontinuation
- 2007-06-29 MA MA30040A patent/MA29119B1/fr unknown
- 2007-06-29 TN TNP2007000248A patent/TNSN07248A1/fr unknown
- 2007-07-27 NO NO20073958A patent/NO20073958L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2005321015A1 (en) | 2006-07-06 |
KR20070086841A (ko) | 2007-08-27 |
TW200637851A (en) | 2006-11-01 |
WO2006070284A1 (en) | 2006-07-06 |
CA2594251A1 (en) | 2006-07-06 |
NL1030819C2 (nl) | 2007-01-04 |
MA29119B1 (fr) | 2007-12-03 |
PE20060775A1 (es) | 2006-09-01 |
UY29317A1 (es) | 2006-07-31 |
EP1838702A1 (en) | 2007-10-03 |
GT200500367A (es) | 2006-08-16 |
CR9135A (es) | 2007-08-14 |
EA200701118A1 (ru) | 2007-12-28 |
TNSN07248A1 (fr) | 2008-11-21 |
NL1030819A1 (nl) | 2006-07-03 |
AR055298A1 (es) | 2007-08-15 |
JP2008526726A (ja) | 2008-07-24 |
CN101087778A (zh) | 2007-12-12 |
IL183188A0 (en) | 2007-08-19 |
AP2007004004A0 (en) | 2007-06-30 |
NO20073958L (no) | 2007-09-27 |
MX2007006301A (es) | 2007-06-15 |
US20060183763A1 (en) | 2006-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0519760A2 (pt) | derivados de pirrolidila de compostos heteroaromÁticos como inibidores de fosfodiesterasse | |
UY30080A1 (es) | Compuestos de heteroarilo biciclicos como inhibidores de pde10 | |
BRPI0513475A (pt) | derivados quinazolin-4-il-piperidina e cinolin-4-il-piperidina como inibidores de pde10 no tratamento de distúrbios do snc | |
BRPI0518508A2 (pt) | compostos de quinolina heteroaromÁticos e seu uso como inibidores de pde10 | |
WO2008001182A8 (en) | Tricyclic heteroaryl compounds as pde10 inhibitors | |
WO2007129183A3 (en) | Bicyclic heteroaryl compounds as pde10 inhibitors | |
WO2008020302A3 (en) | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors | |
ATE384050T1 (de) | Benzazepinderivate als histamin-h3-antagonisten | |
CY1107747T1 (el) | Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης | |
WO2007085954A3 (en) | Aminophthalazine derivative compounds | |
ECSP066474A (es) | Arilindenopiridinas y arilindenopirimidinas y su uso como antagonista del receptor adenosina a2a | |
ATE467636T1 (de) | Pyrazoloä3 , 4-düazepinderivate als histamin-h3- antagonisten | |
BRPI0608437A2 (pt) | derivados tiazol fundidos que possuem afinidade para o receptor histamina h3 | |
DOP2005000273A (es) | Derivados novedosos pirrolidilo de compuestos heteroaromaticos | |
ATE419246T1 (de) | Als antagonisten des muscarinrezeptors geeignete xanthinderivate | |
DOP2007000001A (es) | Compuestos de heteroarilo biciclicos como inhibidores de pde10 | |
TW200716602A (en) | Novel compounds | |
TW200738646A (en) | Novel compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |